Research plan
Closed for comments This consultation ended on at Request commenting lead permission
1 Purpose of this document
NICE recommends that more research is needed on using 2 artificial intelligence (AI) technologies (Deep Ensemble for Recognition of Malignancy [DERM] and Moleanalyzer pro) in teledermatology services to assess and triage skin lesions within the urgent suspected skin cancer pathway, before they can be used in the NHS. More evidence is needed to assess the risk and benefits of the technologies in routine care.
This plan outlines the evidence gaps and what real-world data needs to be collected for a NICE review of the technologies again in the future. It is not a study protocol but suggests an approach to collecting the information needed to address the evidence gaps.
The companies are responsible for ensuring that data collection and analysis takes place. An approach to research is through formation of a consortium, bringing analytical partners and implementation sites together with companies.
When suitable evidence has been collected, the companies should submit the evidence to NICE in a form that can be used for decision making. NICE will review all the evidence and assess whether the technologies can be routinely adopted in the NHS
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions